CA2211118A1 - Stable lipid-comprising drug delivery complexes and methods for their production - Google Patents

Stable lipid-comprising drug delivery complexes and methods for their production

Info

Publication number
CA2211118A1
CA2211118A1 CA002211118A CA2211118A CA2211118A1 CA 2211118 A1 CA2211118 A1 CA 2211118A1 CA 002211118 A CA002211118 A CA 002211118A CA 2211118 A CA2211118 A CA 2211118A CA 2211118 A1 CA2211118 A1 CA 2211118A1
Authority
CA
Canada
Prior art keywords
drug delivery
production
complexes
methods
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002211118A
Other languages
French (fr)
Other versions
CA2211118C (en
Inventor
Xiang Gao
Leaf Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2211118A1 publication Critical patent/CA2211118A1/en
Application granted granted Critical
Publication of CA2211118C publication Critical patent/CA2211118C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the components of the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.
CA002211118A 1995-01-23 1996-01-23 Stable lipid-comprising drug delivery complexes and methods for their production Expired - Lifetime CA2211118C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/376,701 US5795587A (en) 1995-01-23 1995-01-23 Stable lipid-comprising drug delivery complexes and methods for their production
US08/376,701 1995-01-23
PCT/US1996/000816 WO1996022765A1 (en) 1995-01-23 1996-01-23 Stable lipid-comprising drug delivery complexes and methods for their production

Publications (2)

Publication Number Publication Date
CA2211118A1 true CA2211118A1 (en) 1996-08-01
CA2211118C CA2211118C (en) 2009-06-30

Family

ID=23486103

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002211118A Expired - Lifetime CA2211118C (en) 1995-01-23 1996-01-23 Stable lipid-comprising drug delivery complexes and methods for their production

Country Status (14)

Country Link
US (5) US5795587A (en)
EP (1) EP0814777B1 (en)
JP (1) JP4074338B2 (en)
CN (1) CN1177291A (en)
AT (1) ATE227563T1 (en)
AU (1) AU709773B2 (en)
CA (1) CA2211118C (en)
DE (1) DE69624801T2 (en)
DK (1) DK0814777T3 (en)
ES (1) ES2186769T3 (en)
IL (1) IL116856A0 (en)
PT (1) PT814777E (en)
WO (1) WO1996022765A1 (en)
ZA (1) ZA96503B (en)

Families Citing this family (342)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2727679B1 (en) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
ATE210145T1 (en) * 1996-04-12 2001-12-15 Univ Pittsburgh NEW CATIONIC CHOLESTEROL DERIVATIVES WITH CYCLIC POLAR GROUPS
CA2259179C (en) * 1996-07-03 2008-09-23 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
JP4320054B2 (en) 1996-08-13 2009-08-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Compositions and methods for polynucleotide delivery
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
US6436708B1 (en) 1997-04-17 2002-08-20 Paola Leone Delivery system for gene therapy to the brain
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7244714B1 (en) * 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
DK1129064T3 (en) * 1998-11-12 2008-04-28 Invitrogen Corp transfection
US6855549B1 (en) 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP2261335B1 (en) * 1998-11-27 2017-06-14 UCB Pharma S.A. Compositions and methods for increasing bone mineralisation
WO2000047601A1 (en) * 1999-02-15 2000-08-17 Nippon Shinyaku Co. Ltd. Shortened-chain polynucleotides and process for the preparation thereof
AU3243300A (en) * 1999-02-23 2000-09-14 Isis Pharmaceuticals, Inc. Multiparticulate formulation
JP2002538096A (en) * 1999-03-02 2002-11-12 ザ リポソーム カンパニー、インコーポレーテッド Encapsulation of bioactive complex in liposome
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU3366901A (en) * 1999-12-30 2001-07-16 Novartis Ag Novel colloid synthetic vectors for gene therapy
US6514523B1 (en) 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
KR100848973B1 (en) 2000-02-23 2008-07-30 글락소스미스클라인 바이오로지칼즈 에스.에이. Tumour-specific animal proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ATE529435T1 (en) 2000-03-29 2011-11-15 Dgi Biotechnologies L L C AGONISTS AND ANTAGONISTS OF INSULIN AND IGF-1 RECEPTORS
AU6867801A (en) 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
AU2001273149A1 (en) 2000-06-28 2002-01-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
DK2364734T3 (en) * 2000-07-21 2017-10-30 Revance Therapeutics Inc Biological multicomponent transport systems
EP1323415B1 (en) * 2000-10-04 2010-01-13 Kyowa Hakko Kirin Co., Ltd. Method of coating fine particle with lipid film
DE10049010A1 (en) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin polycation / DNA complexes for the systemic therapy of tumor diseases with cytotoxic proteins
CA2437555A1 (en) * 2001-02-01 2002-08-08 Yiyu Zou Stabilised polymeric aerosols for pulmonary gene delivery
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
EP1383480A4 (en) * 2001-04-30 2006-05-24 Targeted Genetics Corp Lipid-comprising drug delivery complexes and methods for their production
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002094983A2 (en) * 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
WO2003040399A2 (en) * 2001-11-02 2003-05-15 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
DK2224012T3 (en) 2001-12-17 2013-05-13 Corixa Corp Compositions and Methods for Therapy and Diagnosis of Inflammatory Bowel Diseases
WO2003066054A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Cationic polymers for use in therapeutic agent delivery
US20060014695A1 (en) * 2002-02-01 2006-01-19 Hamidreza Ghandehari Hpma-polyamine conjugates and uses therefore
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US20060193905A1 (en) * 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
ES2556970T3 (en) 2003-01-06 2016-01-21 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their uses
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DE10322123A1 (en) * 2003-05-12 2004-12-16 Novosom Ag Stable anionic liposome depot system for prolonged release of protein or peptide drugs, e.g. insulin, comprising phosphatidyl choline, cholesterol, anionic lipid(s) and cationic polymer
EP2374819B1 (en) 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
NZ544618A (en) * 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ES2691498T3 (en) * 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Topical application and transdermal release of botulinum toxins
US8974774B2 (en) * 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PT2465534T (en) 2004-06-10 2017-06-27 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
WO2005123776A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
WO2005120495A1 (en) 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
RU2423378C2 (en) 2005-02-08 2011-07-10 Рисерч Дивелопмент Фаундейшн Compositions and methods related to soluble g-protein conjugate receptors (sgpcr)
ZA200707351B (en) * 2005-03-03 2010-02-24 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
WO2006094263A2 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP2392347A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
ITMI20050739A1 (en) * 2005-04-22 2006-10-23 Effebi Spa VALVE-ACTUATOR CONNECTION PLATE
JP5164830B2 (en) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム A novel method for the prevention or treatment of Mycobacterium tuberculosis infection
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
GB2430881B (en) * 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
EP1948230A4 (en) * 2005-11-17 2010-03-10 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
RU2448703C2 (en) 2005-11-23 2012-04-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Oncogenic ras-specific cytotoxic compound and methods for using it
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
US20080226551A1 (en) * 2006-12-29 2008-09-18 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
LT2191001T (en) 2007-04-09 2016-10-10 University Of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
GB0707096D0 (en) * 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
RU2468034C2 (en) 2007-08-27 2012-11-27 ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
UA97559C2 (en) * 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Nucleic acid complex and a nucleic acid delivery composition
JP2011506483A (en) * 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド Fracture treatment method using anti-sclerostin antibody
MX2010012326A (en) * 2008-05-19 2010-12-01 Univ North Carolina Methods and compositions comprising novel cationic lipids.
GB0904942D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904941D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
CN102448982B (en) 2009-03-31 2018-04-20 华盛顿大学 For adjusting the active composition and method of Complement Regulatory Protein on target cell
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
ES2545794T3 (en) 2009-08-28 2015-09-15 Research Development Foundation Urocortin 2 analogues and uses thereof
DK2488203T3 (en) * 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
TW201132353A (en) 2009-12-18 2011-10-01 Amgen Inc WISE binding agents and epitopes
KR20120129927A (en) 2010-01-27 2012-11-28 글락소 그룹 리미티드 Modified tuberculosis antigens
CA2833908C (en) 2010-04-23 2021-02-09 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
PL3486320T3 (en) 2010-04-23 2022-05-09 University Of Florida Research Foundation, Inc. Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
EP2386647A1 (en) * 2010-05-10 2011-11-16 Qiagen GmbH Method for transfecting a eukaryotic cell
HUE033315T2 (en) 2010-05-14 2017-11-28 Amgen Inc High concentration antibody formulations
ES2788198T3 (en) 2010-05-14 2020-10-20 Univ Oregon Health & Science Recombinant hCMV and hCMV vectors encoding a heterologous antigen isolated from hepatitis B virus and uses thereof
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3590949T3 (en) 2010-10-01 2022-08-29 Modernatx, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
CN103649118A (en) 2011-03-01 2014-03-19 安进公司 Bispecific binding agents
CN103517920B (en) 2011-03-25 2018-04-17 安进公司 Anti- hardened proteins (SCLEROSTIN) antibody crystals and its preparation
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2683307T3 (en) 2011-04-08 2018-09-26 University Of Leicester Methods to treat conditions associated with MASP-2-dependent complement activation
CA2870511C (en) 2011-04-21 2023-08-08 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
KR101641057B1 (en) 2011-05-04 2016-07-20 오메로스 코포레이션 Compositions for inhibiting masp-2 dependent complement activation
CN103608030A (en) 2011-06-21 2014-02-26 昂科发克特公司 Compositions and methods for therapy and diagnosis of cancer
EP2729125B1 (en) 2011-07-06 2017-12-13 GlaxoSmithKline Biologicals SA Oil-in-water emulsions that contain nucleic acids
JP6120839B2 (en) 2011-07-06 2017-04-26 ノバルティス アーゲー Cationic oil-in-water emulsion
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
DK2739311T3 (en) 2011-08-04 2018-04-23 Amgen Inc Method of treating bone slit defects
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (en) 2011-10-03 2022-03-31 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2776013B8 (en) 2011-11-08 2023-08-30 The Board of Trustees of the University of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
ES2813524T3 (en) 2011-12-28 2021-03-24 Amgen Inc Method of treating alveolar bone loss using antisclerostin antibodies
CN104203272A (en) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 Composite antigenic sequences and vaccines
JP2015513914A (en) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2869326C (en) 2012-04-06 2021-09-21 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
EP4119577A3 (en) 2012-06-18 2023-11-08 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
CN104619342A (en) 2012-07-05 2015-05-13 Ucb医药有限公司 Treatment for bone diseases
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
SI2922554T1 (en) 2012-11-26 2022-06-30 Modernatx, Inc. Terminally modified rna
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2951205B1 (en) 2013-02-01 2021-08-11 Santa Maria Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014228815B2 (en) 2013-03-15 2019-04-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
JP2016512226A (en) 2013-03-15 2016-04-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Compositions containing buffered aminoalkyl glucosaminide phosphate derivatives and their use to enhance immune responses
DK2970389T3 (en) * 2013-03-15 2020-10-26 Rhythm Pharmaceuticals Inc Pharmaceutical compounds
JP7019233B2 (en) 2013-07-11 2022-02-15 モデルナティエックス インコーポレイテッド Compositions and Methods of Use Containing Synthetic polynucleotides and Synthetic sgRNAs Encoding CRISPR-Related Proteins
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
SG10201801431TA (en) 2013-08-21 2018-04-27 Curevac Ag Respiratory syncytial virus (rsv) vaccine
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016070129A1 (en) 2014-10-30 2016-05-06 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
SI3057993T1 (en) 2013-10-17 2021-03-31 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
LT3066201T (en) 2013-11-07 2018-08-10 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
JP6621409B2 (en) 2013-11-22 2019-12-18 ミナ セラピューティクス リミテッド C / EBPα small molecule activated RNA composition
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
JP6756700B2 (en) 2014-03-18 2020-09-16 ユニバーシティ オブ マサチューセッツ RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
PL3134131T3 (en) 2014-04-23 2022-04-11 Modernatx, Inc. Nucleic acid vaccines
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
EP3160938B1 (en) 2014-06-25 2020-09-16 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN106572974B (en) 2014-07-15 2021-04-23 生命技术公司 Compositions and methods having lipid aggregates for efficient delivery of molecules to cells
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10029012B2 (en) * 2014-09-05 2018-07-24 University Of Pittsuburgh—Of The Commonwealth System Of Higher Education Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
EP3795580A1 (en) 2014-10-03 2021-03-24 University of Massachusetts High efficiency library-identified aav vectors
EP3207150B1 (en) 2014-10-14 2021-04-28 Research Development Foundation Methods for generating engineered enzymes
US10480011B2 (en) 2014-10-21 2019-11-19 University Of Massachusetts Recombinant AAV variants and uses thereof
WO2016065349A2 (en) 2014-10-24 2016-04-28 University Of Maryland, Baltimore Short non-coding protein regulatory rnas (sprrnas) and methods of use
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
CN107249646B (en) 2014-12-16 2021-06-29 内布拉斯加大学董事会 Gene therapy for juvenile batten disease
JP2018504380A (en) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． REVERSIR ™ compounds
KR20170102002A (en) 2015-01-09 2017-09-06 이투빅스 코포레이션 Methods and compositions for the vaccination of Ebola virus
EP3285788A4 (en) 2015-04-23 2018-12-05 University of Massachusetts Modulation of aav vector transgene expression
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
ES2910425T3 (en) 2015-09-17 2022-05-12 Modernatx Inc Compounds and compositions for the intracellular delivery of therapeutic agents
US10829787B2 (en) 2015-10-14 2020-11-10 Life Technologies Corporation Ribonucleoprotein transfection agents
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. Human cytomegalovirus vaccine
MA46317A (en) 2015-10-22 2019-08-07 Modernatx Inc RESPIRATORY SYNCYTIAL VIRUS VACCINE
SI3718565T1 (en) 2015-10-22 2022-08-31 Modernatx, Inc. Respiratory virus vaccines
MX2018004915A (en) 2015-10-22 2019-04-01 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv).
BR112018008090A2 (en) 2015-10-22 2018-11-13 Modernatx Inc herpes simplex virus vaccine.
CN108513575A (en) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 Nucleobase editing machine and application thereof
ES2902477T3 (en) 2015-12-04 2022-03-28 Univ Texas SLC45A2 peptides for immunotherapy
MD3386484T2 (en) 2015-12-10 2022-11-30 Modernatx Inc Compositions and methods for delivery of therapeutic agents
SI3394030T1 (en) 2015-12-22 2022-04-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
DK3394093T3 (en) 2015-12-23 2022-04-19 Modernatx Inc PROCEDURES FOR USING OX40 LIGAND CODING POLYNUCLEOTIDES
US10736960B2 (en) 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
EP3413928B1 (en) 2016-02-12 2022-04-20 University of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
WO2017151823A1 (en) 2016-03-01 2017-09-08 University Of Florida Research Foundation, Inc. Aav vectors for treatment of dominant retinitis pigmentosa
CN115287301A (en) 2016-03-03 2022-11-04 马萨诸塞大学 End-blocked linear duplex DNA for non-viral gene transfer
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
KR20180128941A (en) 2016-03-31 2018-12-04 오메로스 코포레이션 Methods for inhibiting angiogenesis in a subject in need of inhibition of angiogenesis
EP3448364B1 (en) 2016-04-29 2022-02-09 Icahn School of Medicine at Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CA3023174A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212007A1 (en) * 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
JOP20170154B1 (en) 2016-08-01 2023-03-28 Omeros Corp Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
EP4219724A3 (en) 2016-08-23 2023-09-27 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
WO2018071831A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
KR102622411B1 (en) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 AAV delivery of nucleobase editor
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089790A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mrna
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
ES2911186T3 (en) 2017-03-15 2022-05-18 Modernatx Inc Crystalline forms of aminolipids
WO2018170306A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
CN110709095A (en) 2017-04-05 2020-01-17 马萨诸塞大学 Minigene therapy
EP3615510B1 (en) 2017-04-28 2024-03-27 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US20200268666A1 (en) 2017-06-14 2020-08-27 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. Rna formulations
EP3641794A4 (en) 2017-06-23 2021-03-24 The Trustees of Columbia University in the City of New York Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
CN111801345A (en) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE)
TW202402809A (en) 2017-08-15 2024-01-16 美商歐米諾斯公司 Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019048632A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP4219715A3 (en) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US20210236644A1 (en) 2017-11-10 2021-08-05 Cocoon Biotech Inc. Ocular applications of silk-based products
JP7423522B2 (en) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド Polynucleotide encoding ornithine transcarbamylase for the treatment of urea cycle disorders
MA50801A (en) 2017-11-22 2020-09-30 Modernatx Inc POLYNUCLEOTIDES CODING FOR PHENYLALANINE HYDROXYLASE FOR THE TREATMENT OF PHENYLKETONURIS
EP3714045A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
WO2019136241A1 (en) 2018-01-05 2019-07-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019183605A1 (en) 2018-03-23 2019-09-26 University Of Massachusetts Gene therapeutics for treating bone disorders
EP3774879A1 (en) 2018-03-30 2021-02-17 Amgen Inc. C-terminal antibody variants
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
EP4242307A3 (en) 2018-04-12 2023-12-27 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
US11904081B2 (en) 2018-05-11 2024-02-20 Lupagen, Inc. Systems and methods for closed loop, real-time modifications of patient cells
KR20210045360A (en) 2018-05-16 2021-04-26 신테고 코포레이션 Methods and systems for guide RNA design and use
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US20210170005A1 (en) 2018-08-15 2021-06-10 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
EP3849597A1 (en) 2018-09-12 2021-07-21 University of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
MA53609A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED GLUCOSE-6-PHOSPHATASE FOR THE TREATMENT OF GLYCOGENOSIS
WO2020056155A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CA3113353A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3856233A1 (en) 2018-09-27 2021-08-04 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
JP2022501060A (en) 2018-09-28 2022-01-06 プレジデント アンド フェローズ オブ ハーバード カレッジ Mutant reverse tetracycline transactivator for gene expression
US20230048010A1 (en) 2018-09-28 2023-02-16 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
US20220033824A1 (en) 2018-11-29 2022-02-03 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
KR20210138569A (en) 2019-01-11 2021-11-19 아퀴타스 테라퓨틱스 인크. Lipids for Lipid Nanoparticle Delivery of Active Agents
CN113874503A (en) 2019-01-25 2021-12-31 辛瑟高公司 Systems and methods for modulating CRISPR activity
US20220054655A1 (en) 2019-02-22 2022-02-24 University Of Massachusetts Oxr1 gene therapy
AU2020240109A1 (en) 2019-03-19 2021-09-30 President And Fellows Of Harvard College Methods and compositions for editing nucleotide sequences
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3959232A4 (en) 2019-04-24 2023-01-18 University of Massachusetts Aav capsid chimeric antigen receptors and uses thereof
US20220218808A1 (en) 2019-05-02 2022-07-14 University Of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
MA56539A (en) 2019-06-24 2022-04-27 Modernatx Inc ENDONUCLEASE RESISTANT MESSENGER RNA AND USES THEREOF
WO2021026310A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
MX2022001720A (en) 2019-08-14 2022-03-11 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids.
WO2021050970A1 (en) 2019-09-13 2021-03-18 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
CN114728887A (en) 2019-09-19 2022-07-08 摩登纳特斯有限公司 Branched tail end lipid compounds and compositions for intracellular delivery of therapeutic agents
KR20220110530A (en) 2019-12-04 2022-08-08 오메로스 코포레이션 MASP-2 Inhibitors and Methods of Use
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2021195218A1 (en) 2020-03-24 2021-09-30 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
AU2021244555A1 (en) 2020-03-24 2022-11-24 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
AR122404A1 (en) 2020-03-31 2022-09-07 Univ Massachusetts CAPSID VARIANTS AND USES THEREOF
CA3174187A1 (en) 2020-04-01 2021-10-07 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2
US20210403946A1 (en) 2020-04-29 2021-12-30 The Broad Institute, Inc. Machine learning accelerated protein engineering through fitness prediction
US20210346416A1 (en) * 2020-05-05 2021-11-11 Ralph Lipp Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2021237068A2 (en) 2020-05-21 2021-11-25 Board Of Regents, The University Of Texas System T cell receptors with vgll1 specificity and uses thereof
EP4158005A1 (en) 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalanine hydroxylase variants and uses thereof
MX2023001998A (en) 2020-08-17 2023-05-04 Massachusetts Inst Technology Shank3 gene therapy approaches.
IL302625A (en) 2020-11-13 2023-07-01 Modernatx Inc Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022120080A1 (en) 2020-12-03 2022-06-09 University Of Massachusetts Development of novel gene therapeutics for fibrodysplasia ossificans progressiva
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US11859021B2 (en) 2021-03-19 2024-01-02 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
CA3214137A1 (en) 2021-03-26 2022-09-29 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3216585A1 (en) 2021-04-27 2022-11-03 Nathaniel SILVER Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2022232286A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
BR112023023486A2 (en) 2021-05-10 2024-01-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd PHARMACEUTICAL COMPOSITION, AND, METHOD OF TREATMENT OF A DISEASE OR CONDITION IN WHICH A BENEFICIAL CLINICAL EFFECT IS OBTAINED BY THE REDUCTION IN NEURONAL NITRIC OXIDE SYNTHASE ACTIVITY
WO2022266083A2 (en) 2021-06-15 2022-12-22 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056329A1 (en) 2021-09-30 2023-04-06 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
TW202334080A (en) 2021-11-08 2023-09-01 美商歐納醫療公司 Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023095874A1 (en) * 2021-11-25 2023-06-01 国立大学法人長崎大学 Lipid compound, liposome, exosome, lipid nanoparticle and drug delivery system
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
CN114306641A (en) * 2022-02-17 2022-04-12 大连民族大学 Cholesterol amino derivative-sucrose ester type cationic liposome/gene complex and preparation method thereof
WO2023164545A1 (en) 2022-02-23 2023-08-31 Massachusetts Institute Of Technology Methods for upregulating shank3 expression
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) * 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) * 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5342921A (en) * 1985-03-28 1994-08-30 Chiron Corporation Superoxide dismutase fusion polypeptides for expression of mammalian proteins
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5540933A (en) * 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0238645A1 (en) 1985-10-03 1987-09-30 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5560929A (en) 1986-08-18 1996-10-01 The Dow Chemical Company Structured copolymers and their use as absorbents, gels and carriers of metal ions
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5283634A (en) * 1987-06-18 1994-02-01 Canon Kabushiki Kaisha Luminance signal correcting method
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5043164A (en) * 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
DE3908047A1 (en) 1989-03-13 1990-09-20 Desitin Arzneimittel Gmbh HIGH DISPERSES PHARMACEUTICAL COMPOSITION
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5165925A (en) 1989-05-02 1992-11-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Vaccine for immunizing fish against infectious pancreatic necrosis virus
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
ES2091916T3 (en) 1989-12-21 1996-11-16 Whitehead Biomedical Inst METHOD FOR SUPPLYING MOLECULES INSIDE EUCARIOTIC CELLS.
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5583198A (en) 1989-12-22 1996-12-10 Commonwealth Scientific And Industrial Research Organization Amino acids, peptides or derivatives thereof coupled to fats
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
NZ239893A (en) * 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell
DE69121903T2 (en) * 1990-12-04 1997-04-10 Univ Texas METHODS AND COMPOSITIONS TO SUPPRESS CELL INFORMATION BY NEW
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
CA2115140A1 (en) * 1991-08-07 1993-02-18 Lola M. Reid Proliferation of hepatocyte precursors
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
DE4139001A1 (en) 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh PROCESS FOR INJECTION OF NUCLEAR ACIDS IN CELLS
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
PT643835E (en) * 1992-02-24 2001-10-30 Genelabs Tech Inc TEST AND METHOD FOR HTLV-I / HTLV-II
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
US6033884A (en) * 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
JPH07505283A (en) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン DNA transporter system and method of use
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
DE69333434T2 (en) 1992-04-03 2005-03-03 The Regents Of The University Of California, Oakland SELF-ORGANIZING SYSTEM FOR THE ADMINISTRATION OF POLYNUCLEOTIDES CONTAINING AN AMPHIPHATIC PEPTIDE
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5266106A (en) 1992-10-22 1993-11-30 Xerox Corporation Ink compositions with dendrimer grafts
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
WO1994018834A1 (en) * 1993-02-16 1994-09-01 Virginia Tech Intellectual Properties, Inc. Polyelectrolyte dna conjugation and genetic transformation of an animal
US5491074A (en) * 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
DE4311651A1 (en) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
AU6568594A (en) 1993-04-14 1994-11-08 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
US5776486A (en) * 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
WO1994027435A1 (en) * 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
WO1995002397A1 (en) 1993-07-14 1995-01-26 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
PT733103E (en) * 1993-11-09 2004-07-30 Targeted Genetics Corp CREATION OF HIGH RECOMBINANT AAV VECTOR TITLES
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5759805A (en) * 1994-01-28 1998-06-02 Targeted Genetics Corporation And Immunex CD69 transcriptional regulatory elements
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US6077835A (en) * 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
JP4285766B2 (en) 1994-03-23 2009-06-24 オハイオ ユニバーシティ Deliver to dense nucleic acids and cells
FR2719316B1 (en) * 1994-04-28 1996-05-31 Idm New nucleic acid and polymer complexes, their preparation process and their use for cell transfection.
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5744355A (en) * 1994-10-18 1998-04-28 Mayo Foundation For Medical Education And Research cDNA cloning and expression of human liver estrogen sulfotransferase
US5627159A (en) * 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5587441A (en) 1994-11-08 1996-12-24 Cornell Research Foundation, Inc. Hyperbranched polymers from AB monomers
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
DE69634084T2 (en) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. PREPARATION OF LIPID NUCLEIC ACID PARTICLES A HYDROPHOBIC LIPID NUCLEIC ACID COMPLEX INTERMEDIATE PRODUCT AND FOR THE USE IN THE TRANSFER OF THE INVENTION
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
JP4338106B2 (en) * 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション Peptide enhanced cationic lipid transfection
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6033848A (en) * 1995-08-01 2000-03-07 Incyte Pharmaceuticals, Inc. Human ice homolog
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6086913A (en) * 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
US6126964A (en) 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
AUPN741696A0 (en) 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5811297A (en) 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
JPH09268195A (en) * 1996-04-02 1997-10-14 Mitsubishi Chem Corp Production of sucrose fatty acid ester
ATE252891T1 (en) * 1996-08-26 2003-11-15 Transgene Sa CATIONIC LIPID-NUCLIC ACID COMPLEXES
US5905777A (en) * 1996-09-27 1999-05-18 At&T Corp. E-mail paging system
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6224903B1 (en) * 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
JP2002500201A (en) * 1998-01-05 2002-01-08 ユニバーシティ オブ ワシントン Enhanced transport using membrane disruptors
US6271209B1 (en) * 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6043390A (en) * 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
US6011202A (en) * 1998-07-28 2000-01-04 Delta And Pine Land Company Soybean cultivar 95-00981
DK1129064T3 (en) * 1998-11-12 2008-04-28 Invitrogen Corp transfection
US6773920B1 (en) * 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
WO2002034879A2 (en) * 2000-10-27 2002-05-02 Invitrogen Corporation Method for introducing antisense oligonucleotides into eucaryotic cells
US20040102606A1 (en) * 2001-04-24 2004-05-27 Danuta Balicki Histone H2A -derived peptides useful in gene delivery
EP1383480A4 (en) * 2001-04-30 2006-05-24 Targeted Genetics Corp Lipid-comprising drug delivery complexes and methods for their production
WO2004063342A2 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes

Also Published As

Publication number Publication date
JP4074338B2 (en) 2008-04-09
CA2211118C (en) 2009-06-30
EP0814777B1 (en) 2002-11-13
EP0814777A1 (en) 1998-01-07
US20130281382A1 (en) 2013-10-24
US8771728B2 (en) 2014-07-08
US20100184953A1 (en) 2010-07-22
IL116856A0 (en) 1996-07-23
PT814777E (en) 2003-03-31
ES2186769T3 (en) 2003-05-16
ATE227563T1 (en) 2002-11-15
DE69624801D1 (en) 2002-12-19
US20080153166A1 (en) 2008-06-26
AU709773B2 (en) 1999-09-09
CN1177291A (en) 1998-03-25
MX9705572A (en) 1998-06-28
JPH10512882A (en) 1998-12-08
DE69624801T2 (en) 2003-04-10
US5795587A (en) 1998-08-18
WO1996022765A1 (en) 1996-08-01
ZA96503B (en) 1996-08-07
AU4703796A (en) 1996-08-14
US7655468B2 (en) 2010-02-02
DK0814777T3 (en) 2003-03-03
US7993672B2 (en) 2011-08-09
US20120178702A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CA2211118A1 (en) Stable lipid-comprising drug delivery complexes and methods for their production
HU9200823D0 (en) Process for the production of cyclical carbamide derivatives and medical preparations containing them as active agents
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
WO2002101006A3 (en) Production of proteins in plants
AU6701890A (en) Process for the production of biologically active protein
AU6194694A (en) Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
ES2058411T3 (en) SUBSTANCE FR 901228 AND ITS PREPARATION.
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
HUP9802578A3 (en) Phenylacetic acid derivatives, process and intermediates for producing them, fingicide, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients and use thereof
UA43348C2 (en) Aqueous pharmaceutical composition, which includes the factor of the nerve growth factor (variants) and liophilic pharmaceutical composition
CA2079342A1 (en) Multi-functional pharmaceutical compounds and methods of use
AU1159400A (en) Substituted 4-amino-2-aryl-cyclopenta(D)pyrimidines, their production and use and pharmaceuticalreparations containing same
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
GR1001597B (en) Novel biologically active eburnamenine derivatives, pharmaceutical compositions containing them and process for preparing same.
DK0804228T3 (en) Drug containing the protein C activation peptide
DK347788D0 (en) TEICOPLAN-SIMILAR COMPOUNDS, PROCEDURES AND MICRO-ORGANISMS FOR PRODUCING THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
ATE25708T1 (en) BIOLOGICALLY ACTIVE CONJUGATES, THEIR PRODUCTION AND USE.
IL125474A0 (en) Solid instant-release forms of administration and process for producing the same
EP0333000A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
MY114693A (en) Substituted benzenesulfonylureas and thioureas,processes for their preparation,their use for the production of pharmaceutical preparations, and pharmaceutical preparation containing them
HUP0202974A2 (en) Metal-containing ribonucleotide polypeptides
CA2217729A1 (en) Substance fa-70d, process for producing the same, and uses thereof
AU625831B2 (en) Solubilization of t-pa

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160125